European journal of gastroenterology & hepatology
Second-line infliximab therapy for ulcerative colitis (SLIT-UC): a retrospective cohort study.
Ciarán P C Galts, Sama Anvari, Mawiyah Haq, Kevin Grossman, Dorota Borovsky, Aaron Wen, Emily C L Wong, Hiu-Ki Rachel Tran, Abdulrahman Albassam, Smita Halder, John K Marshall, Neeraj Narula
Published: 202610.1097/MEG.0000000000003132
Abstract
BACKGROUND: Infliximab's efficacy as a second-line agent in moderate or severe ulcerative colitis after prior advanced therapy failure is unclear. Registration trials for infliximab did not assess its efficacy after exposure to other advanced therapi…
Preview only. Read the full abstract at the source